CN1678347A - 抗体及其应用 - Google Patents

抗体及其应用 Download PDF

Info

Publication number
CN1678347A
CN1678347A CNA038204029A CN03820402A CN1678347A CN 1678347 A CN1678347 A CN 1678347A CN A038204029 A CNA038204029 A CN A038204029A CN 03820402 A CN03820402 A CN 03820402A CN 1678347 A CN1678347 A CN 1678347A
Authority
CN
China
Prior art keywords
antibody
cell
fragment
patient
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038204029A
Other languages
English (en)
Chinese (zh)
Inventor
A·莱瓦农
R·本-莱维
D·普拉克辛
E·桑顿
Y·哈加尔
H·霍奇马－哈伊姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of CN1678347A publication Critical patent/CN1678347A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
CNA038204029A 2002-07-01 2003-06-30 抗体及其应用 Pending CN1678347A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01
US10/189,032 2002-07-01

Publications (1)

Publication Number Publication Date
CN1678347A true CN1678347A (zh) 2005-10-05

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038204029A Pending CN1678347A (zh) 2002-07-01 2003-06-30 抗体及其应用

Country Status (12)

Country Link
EP (1) EP1534332A4 (fr)
JP (1) JP2005536199A (fr)
KR (1) KR20060011925A (fr)
CN (1) CN1678347A (fr)
AU (1) AU2003263764A1 (fr)
BR (1) BR0312483A (fr)
CA (1) CA2491363A1 (fr)
IL (1) IL166063A0 (fr)
MX (1) MXPA05000272A (fr)
PL (1) PL374439A1 (fr)
RU (1) RU2005101621A (fr)
WO (1) WO2004003166A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112740043A (zh) * 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
NZ590478A (en) 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
WO2007067983A2 (fr) * 2005-12-09 2007-06-14 Wyeth Anticorps specifique de la sulfotyrosine et utilisation a cet effet
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
EP2718325A4 (fr) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A Anticorps anti-psgl-1 et leurs utilisations
KR20150044877A (ko) 2012-06-22 2015-04-27 젠티엄 에스피에이 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide
KR101896751B1 (ko) * 2015-12-01 2018-10-04 주식회사 엘지화학 열가소성 수지, 이의 제조방법 및 이를 포함하는 열가소성 수지 조성물
CN111715409B (zh) * 2020-07-01 2021-07-23 中南大学 一种微细粒方铅矿的组合铅抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142717A0 (en) * 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
BR0109524A (pt) * 2000-03-24 2004-01-20 Genetics Inst Molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um polipeptìdeo, polipeptìdeo isolado, anticorpo, método para detectar a presença de um polipeptìdeo em uma amostra, kit, e, métodos para detectar a presença de uma molécula de ácido nucleico em uma amostra, para identificar um composto e para modular a atividade de um polipeptìdeo

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112740043A (zh) * 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体

Also Published As

Publication number Publication date
KR20060011925A (ko) 2006-02-06
AU2003263764A1 (en) 2004-01-19
BR0312483A (pt) 2005-08-09
JP2005536199A (ja) 2005-12-02
RU2005101621A (ru) 2005-11-20
MXPA05000272A (es) 2005-09-20
EP1534332A2 (fr) 2005-06-01
IL166063A0 (en) 2006-01-15
PL374439A1 (en) 2005-10-17
EP1534332A4 (fr) 2006-11-22
WO2004003166A3 (fr) 2005-03-10
CA2491363A1 (fr) 2004-01-08
WO2004003166A2 (fr) 2004-01-08

Similar Documents

Publication Publication Date Title
EP2850106B1 (fr) Immunofusion bispécifique (ifb) de scfv se liant au cd123 et cd3
JP4787750B2 (ja) Ｃｄ２０結合性ポリペプチド構成物
CN1271205C (zh) 重新构建的人抗hm1.24抗体
CN1922199A (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
CN108409862B (zh) I型干扰素受体抗体及其用途
CN1795009A (zh) 抗－cd33抗体和使用其治疗急性髓性白血病的方法
CN1620468A (zh) 新的抗igf－ir抗体及其应用
CN101044242A (zh) 肿瘤特异性抗体
CN101076542A (zh) 特异性针对肝细胞癌和其他癌的抗体及其用途
CN1816352A (zh) 使用一种免疫毒素治疗癌症的方法
CN102428103A (zh) 抗light的人源化抗体及其使用
CN111836828A (zh) 包括抗原结合结构域和运送部分的多肽
CN100347194C (zh) 分离的包括含硫酸根部分的表位的分子,抗这样的表位的抗体,和它们的应用
EP3431504B1 (fr) Anticorps d4 anti-phospholipase
US20090191211A1 (en) METHODS FOR DAMAGING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES
CN1675244A (zh) Mcam抑制剂
CN101048425A (zh) Kid3及与其结合的kid3抗体
CN112442132A (zh) 靶向肿瘤的重组双功能融合蛋白及其应用
CN1642983A (zh) 抗C5aR抗体及其应用
CN1639185A (zh) 癌相关表位
RU2725807C2 (ru) Растворимый универсальный усиливающий adcc синтетический слитный ген, пептидная технология и их применение
CN1678347A (zh) 抗体及其应用
CN1551886A (zh) 用于选择性癌症治疗的特异性人抗体
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
CN1279056C (zh) 肿瘤相关抗原sm5－1的特异性抗体及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication